A research study comparing how well different doses of the medicine NNC0519-0130 help people with excess body weight lose weight(NN9541-5015)

Investigation of the safety and efficacy of once weekly NNC0519-0130 in participants with overweight or obesity - a dose finding study(NN9541-5015) - NA

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051230198

Enrollment

Registered

2024-03-11

Start date

2024-03-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

This is an interventional, 36-week, multi-national, multi-centre, randomised, 13 armed, parallel group, dose-finding phase 2 study. The study will be double-blinded within dose level of once weekly (Q

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a) BMI >=27.0 kg/m2 with the presence of at least one weight-related co morbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. b) BMI >= 30.0 kg/m2.

Exclusion criteria

Exclusion criteria: History of type 1 or type 2 diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Change from baseline in body weight (%)	—

Countries

Australia, Japan, United States

Contacts

Public ContactAdministorator Clinical trail information

Novo Nordisk Pharma Ltd.

jphc_clinical_trials@novonordisk.com+81-362661000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026